Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 6/20 | 0.46 |
| ▸ | HTR2C | P28335 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12988949 | 0.88 | LPAR1 (0.72) | LPAR1MEN1KMT2ALPAR3 | |
| SCHEMBL12989367 | 0.88 | LPAR1 (0.72) | LPAR1MEN1KMT2ALPAR3 | |
| SCHEMBL12989052 | 0.81 | LPAR1 (0.73) | LPAR1MEN1KMT2ALPAR3 | |
| SCHEMBL30005304 | 0.81 | LPAR1 (0.73) | LPAR1MEN1KMT2ALPAR3 | |
| SCHEMBL16477201 | 0.74 | LPAR1 (0.74) | LPAR1LPAR3 | |
| SCHEMBL13195363 | 0.74 | LPAR1 (0.87) | LPAR1LPAR3 | |
| SCHEMBL15897414 | 0.73 | LPAR1 (0.72) | LPAR1LPAR3 | |
| SCHEMBL17083212 | 0.72 | LPAR1 (1.00) | LPAR1LPAR3 | |
| SCHEMBL12989271 | 0.72 | LPAR1 (0.52) | LPAR1MEN1KMT2ALPAR3 | |
| SCHEMBL12989040 | 0.71 | LPAR1 (0.74) | LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317131-A1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317131-A1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | LPAR1, LPAR2, LPAR3 | LPAR1 1/4885MEN1 3637/4885KMT2A 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.